Unless specified, the following frequency categories were calculated from the number of adverse events reported in a large phase III study conducted in 9366 postmenopausal women with operable breast cancer treated for 5 years and unless specified, no account was taken of the frequency within the comparative treatment group or whether the investigator considered it to be related to study medication. (See table.)
Click on icon to see table/diagram/image
In a large phase III study conducted in 9366 postmenopausal women with operable breast cancer treated for 5 years, ischemic cardiovascular events were reported more frequently in patients treated with Anastrozole (ARIMIDEX) compared to those treated with tamoxifen, although the difference was not statistically significant. The observed difference was mainly due to more reports of angina pectoris and was associated with a sub-group of patients with pre-existing ischemic heart disease.